Pay in 4 interest-free payments of $5.26 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Snijder MB, Dekker JM, Visser M, Bouter LM, Stehouwer CD, Kostense PJ, et al
Even clinicians who are not as familiar with these medications will ask me, 'I have a patient on Mounjaro who's not losing weight can we switch to Zepbound? without realizing its exactly the same drug. To complicate matters, pharmaceutical companies are quickly working on new drugs including triple agonists that target GLP-1, GIP and glucagon receptors as well as oral versions of each drug
What the clinical evidence shows Several large, peer-reviewed studies have quantified the risk: The STEP 1 trial (NEJM, 2021): patients on high-dose semaglutide lost an average of 14.9% of their body weight over 68 weeks
This study analysed a group of Dutch Caucasians with a polymorphism in the promoter of the IGF-1 gene [129, 218]
Epub 2009 Dec 25
This molecule, as well as the broader pipeline, placed Metsera at the centre of a fierce bidding war between Pfizer and Novo Nordisk in late 2025, with an eventual deal value of around ~US$10bn
